©The Author(s) 2025.
World J Clin Oncol. Oct 24, 2025; 16(10): 110511
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110511
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110511
Figure 5 Subgroup analysis by number of immune checkpoint inhibitor cycles (≤ 2 vs > 2).
A and B: No significant subgroup differences were observed for (A) pathological complete response and (B) overall response rate; C: Shorter regimens (≤ 2 cycles) were associated with a significantly higher resection rate compared to longer regimens. 95%CI: 95% confidence interval.
- Citation: Cicerone O, Oliviero B, Mantovani S, Maiocchi L, Ravetta V, Berton F, Corallo S, Vanoli A, Maestri M. Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence. World J Clin Oncol 2025; 16(10): 110511
- URL: https://www.wjgnet.com/2218-4333/full/v16/i10/110511.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i10.110511